Can a durable disease-free survival be achieved with surgical resection in patients with pathological node positive renal cell carcinoma?

• Published in: The Journal of urology Vol. 186; no. 4; p. 1236
• Main Authors: Delacroix, Jr, Scott E, Chapin, Brian F, Chen, Jaclyn J, Nogueras-Gonzalez, Graciela M, Tamboli, Pheroze, Matin, Surena F, Wood, Christopher G
• Format: Journal Article
• Language: English
• Published: United States 01-10-2011
• Subjects: Carcinoma, Renal Cell - mortality; Carcinoma, Renal Cell - pathology; Carcinoma, Renal Cell - secondary; Carcinoma, Renal Cell - surgery; Disease-Free Survival; Humans; Kidney Neoplasms - mortality; Kidney Neoplasms - pathology; Kidney Neoplasms - surgery; Lymph Node Excision; Lymphatic Metastasis; Nephrectomy; Proportional Hazards Models; Survival Rate
• ISSN: 1527-3792
• DOI: 10.1016/j.juro.2011.05.051

Patients with isolated regional nodal metastases from renal cell carcinoma are a distinct cohort for which resection of involved lymph nodes may be therapeutic. We assessed the outcomes of patients treated at our institution with pathological node positive renal cell carcinoma without concomitant metastatic disease (T(any)N+M0).
A total of 2,521 patients with nonmetastatic renal cell carcinoma (T(any)N(any)M0) of any histological subtype treated with nephrectomy were identified between 1995 and 2009. Pathological regional node positive disease in the absence of clinically detectable metastases (T(any)N(1-2)M0) was present in 68 patients (2.7%) and these patients formed our study cohort. Patients were assessed for timing and location of recurrence, disease specific survival and overall survival. Multivariate Cox regression analysis was performed to define factors predictive of recurrence and overall survival.
Of the 68 patients with T(any)N(1-2)M0 renal cell carcinoma 22.1% were free of disease at a median followup of 43.5 months. In those patients experiencing recurrence, disease was detected within the first 4 months after surgery in 51% and was most commonly detected at multiple organ sites. The Kaplan-Meier estimated 5-year overall survival and disease specific survival was 37% and 39%, respectively. Predictors of a favorable outcome included an Eastern Cooperative Oncology Group performance status of 0, single node involvement, absence of sarcomatoid features and papillary histology.
Nephrectomy with lymph node dissection can provide a durable disease-free survival in a proportion of patients with regionally advanced renal cell carcinoma and limited lymph node metastases.